Danapha Pharmaceutical JSC

Danapha Pharmaceutical JSC operates with a debt-to-equity ratio of 0.8, indicating a moderate reliance on debt financing. The company's liquidity is assessed as medium, with a current ratio of 1.27, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -116.9 billion VND, and capital expenditures are substantial at -219.2 billion VND, indicating significant reinvestment in operations. Profitability metrics show a return on equity of 10.08% and a return on assets of 3.93%. These figures are below the industry median for ROE and ROA in the Pharmaceuticals sector, suggesting Danapha is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in Vietnam, with no disclosed international revenue segments. It operates in a single business segment focused on pharmaceutical manufacturing and distribution. The lack of geographic diversification and segment breakdown increases exposure to local economic and regulatory risks. Growth trajectory is mixed. Revenue for the latest period is 647.3 billion VND, but no year-over-year growth rate is provided. The outlook for the current fiscal year is neutral, with no significant revenue or margin expansion expected. The next fiscal year is projected to show similar performance, with no clear drivers of growth identified. Risk factors include medium liquidity risk due to negative net cash after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure from share issuance. However, the company's reliance on long-term debt (677.8 billion VND) and negative free cash flow could limit flexibility in capital allocation. Recent events include no disclosed filings or transcripts in the provided data. The company's financial snapshot does not include recent earnings calls or regulatory updates, limiting visibility into management commentary or strategic shifts.